Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV3YMX)

• Drug Name: Vedolizmab Drug Info
• Synonyms: 4168-17-6

Indication

Disease Entry	ICD 11	Status	REF
Crohn disease	DD70	Approved	[1]
Ulcerative colitis	DD71	Approved	[1]

• Cross-matching ID: TTD Drug ID: DMV3YMX

Molecule-Related Drug Atlas

Drug(s) Targeting Integrin beta-7 (ITGB7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rhumab Beta7	DMGOTK4	Ulcerative colitis	DD71	Phase 3	[3]
AMG-181	DMODJTX	Crohn disease	DD70	Phase 2	[4]
PTG-100	DMQNRGE	Ulcerative colitis	DD71	Phase 1	[5]

Drug(s) Targeting Integrin alpha-4 (ITGA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Antegren	DMNC64R	Multiple sclerosis	8A40	Approved	[6]
Natalizumab	DMAK85L	Crohn disease	DD70	Approved	[7]
PB006	DMVHGLA	Crohn disease	DD70	Phase 3	[8]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[9]
AMG-181	DMODJTX	Crohn disease	DD70	Phase 2	[5]
Senktide	DMOH8LD	Epilepsy	8A60-8A68	Phase 2	[10]
BIO-1211	DMKICA3	Asthma	CA23	Phase 2	[11]
PTG-100	DMQNRGE	Ulcerative colitis	DD71	Phase 1	[5]
ELND-002	DMM9S51	Autoimmune diabetes	5A10	Phase 1	[12]
ELND-004	DMLQYVD	Autoimmune diabetes	5A10	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Integrin alpha-4 (ITGA4)	TT4BT06	ITA4_HUMAN	Antagonist	[2]
Integrin beta-7 (ITGB7)	TTLT9XQ	ITB7_HUMAN	Antagonist	[2]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Clinical pipeline report, company report or official report of Takeda (2009).
• [3] A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut. 2013 Aug;62(8):1122-30.
• [4] Pharmacology of AMG 181, a human anti-alpha4 beta7 antibody that specifically alters trafficking of gut-homing T cells. Br J Pharmacol. 2013 May;169(1):51-68.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr Opin Chem Biol. 1998 Aug;2(4):453-7.
• [7] Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring. Front Immunol. 2020 Sep 24;11:549842.
• [8] Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial. JAMA Neurol. 2023 Mar 1;80(3):298-307.
• [9] Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] A small-molecule, tight-binding inhibitor of the integrin alpha(4)beta(1) blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):603-11.
• [12] Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol. 2003 Jun 15;170(12):5912-8.